Inhibikase Therapeutics (IKT) FCF Margin (2020 - 2023)
Inhibikase Therapeutics (IKT) posted quarterly FCF Margin of 344243100.0% for Q4 2023, down 34423750523.0% year-over-year from N/an in Q4 2022, and down 6672362.53% quarter-over-quarter from 5159.16% in Q3 2023.
Inhibikase Therapeutics (IKT) FCF Margin (2020 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported FCF Margin for 4 consecutive years, with 344243100.0% the latest figure, recorded in Q4 2023.
- In Q4 2023, FCF Margin fell 34423750523.0% year-over-year to 344243100.0%; the TTM figure through Sep 2024 stood at 1724492300.0% (down 172448668417.0% YoY), while the FY2023 annual figure was 6947.87%, up 730549.0% from the prior year.
- FCF Margin declined to 344243100.0% in Q4 2023 per IKT's latest filing, from 5159.16% in the prior quarter.
- Across five years, FCF Margin topped out at 200.41% in Q3 2020 and bottomed at 344243100.0% in Q4 2023.
- Historically, FCF Margin has averaged 21539540.75% across 4 years, with a median of 4540.49% in 2023.
- Annual changes were most pronounced in 2022 — FCF Margin jumped 20509540 bps — and 2023, when it plunged 2000000000 bps.
- Inhibikase Therapeutics' FCF Margin stood at 555.42% in 2020, then slumped by 37833 bps to 210690.17% in 2021, then jumped by 97 bps to 5594.77% in 2022, then sank by 6152840 bps to 344243100.0% in 2023.
- Business Quant data shows IKT's FCF Margin at 344243100.0% in Q4 2023, 5159.16% in Q3 2023, and 3921.82% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -344,243,100.00% |
| Sep 30, 2023 | -5,159.16% |
| Jun 30, 2023 | -3,921.82% |
| Mar 31, 2023 | -9,256.10% |
| Dec 31, 2022 | -5,594.77% |
| Sep 30, 2022 | -78,245.73% |
| Jun 30, 2022 | -66,480.49% |
| Mar 31, 2022 | -8,546.84% |
| Dec 31, 2021 | -210,690.17% |
| Sep 30, 2021 | -615.14% |
| Jun 30, 2021 | -311.55% |
| Mar 31, 2021 | -279.58% |
| Dec 31, 2020 | -555.42% |
| Sep 30, 2020 | 200.41% |
| Jun 30, 2020 | -1.33% |
| Mar 31, 2020 | -94.33% |